secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001104659-23-071430
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx reports Phase 2 CF data: ELX-02 shows +2.83% ppFEV1 in 6 responders, supports pivotal trial
--------------------------------------------------------------------------------

- 13 evaluable patients; 6 responders had +2.83% mean ppFEV1 increase at Day 35 vs Day 1.
- Overall ppFEV1 change was -0.31% at Day 35; disease progression pre-treatment averaged -4.26%/yr.
- Safety follow-up at 28 days showed -2.69% ppFEV1 decline; no treatment-related serious adverse events.
- Results bolster decision to advance ELX-02 into pivotal Alport syndrome trial.
- Interim topline from 11 patients reported Sep 2022; final analysis confirms activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923071430/0001104659-23-071430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923071430/tm2318799d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-071430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer